Company intelligence / Profile preview
Axovia Therapeutics
London, England, United Kingdomaxoviatherapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Robust preclinical efficacy and toxicology data have been reported for the lead program AXV101, showing disease modification including rescue of vision loss by halting retinal degeneration in animal models. No human clinical results yet as trials are scheduled to begin mid/late 2025.
- Therapeutic areas
- EndocrinologyRare Diseases
- Modalities
- Gene therapy using adeno-associated virus vectors (AAV9)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
ALSA VenturesUniversity College LondonAlbionVCA Race Against Blindness grant funding ($1M)Academic collaboration roots at University College London via co-founders’ research.
Beyond the preview
Go deeper on Axovia Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Axovia Therapeutics.